Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

Summary

Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of substances called ketone bodies) observed with SGLT2i therapy in T1D.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Diabetic Nephropathies
• Kidney Failure, Chronic
• Diabetes Mellitus Type 1
• Heart Failure

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

18 to 75 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Alessandro Doria

Last updated on ClinicalTrials.gov

March 24, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites